IP Library Granted Patent US 7,615,637
Granted Patent B2
US 7,615,637 · App. 12/269,690 · Granted Nov 10, 2009

Transition metal complexes with (pyridyl)imidazole ligands

Assignee: Abbott Diabetes Care Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,637
App. No.
12/269,690
Granted
Nov 10, 2009
Kind
B2
Abstract

Novel transition metal complexes of iron, cobalt, ruthenium, osmium, and vanadium are described. The transition metal complexes can be used as redox mediators in enzyme-based electrochemical sensors. The transition metal complexes include substituted or unsubstituted (pyridyl)imidazole ligands. Transition metal complexes attached to polymeric backbones are also described.

Claims (58)

1. A complex having the formula:

wherein c is a negative, neutral, or positive charge represented by −1 to −5, 0, or +1 to +5, inclusive, respectively;

M is osmium or ruthenium;

L 1 is a substituted or an unsubstituted heterocyclic nitrogen-containing ligand sufficient to spatially or stereochemically shield M;

L 2 is a negatively charged ligand; and

L and L′ are independently:

wherein R′ 1 is a substituted or an unsubstituted alkyl, alkenyl or aryl;

each of R a and R b is independently —H, —F, —Cl, —Br, —I, —NO 2 , —CN, —CO 2 H, —SO 3 H, —NHNH 2 , —SH, —OH, —NH 2 , or substituted or unsubstituted alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, arylcarboxamido, hydrazino, alkylhydrazino, hydroxylamino, alkoxylamino, alkylthio, alkenyl, aryl, or alkyl;

each of R c and R d is independently —H, —F, —Cl, —Br, —I, —NO 2 , —CN, —CO 2 H, —SO 3 H, —NHNH 2 , —SH, —OH, —NH 2 , or substituted or unsubstituted alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, arylcarboxamido, hydrazino, alkylhydrazino, hydroxylamino, alkoxylamino, alkylthio, alkenyl, aryl, or alkyl, or a combination of R c and R d forms a saturated or an unsaturated 5- or 6-membered ring; and

each of R′ 3 and R′ 4 is independently —H, —F, —Cl, —Br, —I, —NO 2 , —CN, —CO 2 H, —SO 3 H, —NHNH 2 , —SH, —OH, —NH 2 , or substituted or unsubstituted alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, arylcarboxamido, hydrazino, alkylhydrazino, hydroxylamino, alkoxylamino, alkylthio, alkenyl, aryl, or alkyl, or a combination of R′ 3 and R′ 4 forms a saturated or an unsaturated 5- or 6-membered ring.

2. The complex of claim 1 , wherein

M is osmium;

L 2 is a halide; and

L and L′ are independently:

wherein R′ 1 is a substituted or an unsubstituted C1-C6 alkyl;

R′ 3 and R′ 4 are independently —H;

R a , R b , R c and R d are independently —H or C1 alkyl;

c is a negative, neutral, or positive charge represented by −1 to −5, 0, or +1 to +5, inclusive, respectively.

3. The complex of claim 2 , wherein L 1 is a substituted or unsubstituted pyridine.

4. The complex of claim 2 , wherein L 1 has the formula:

wherein R 11 , R 12 , R 13 , R 14 and R 15 are independently —H, —F, —Cl, —Br, —I, —NO 2 , —CN, —CO 2 H, —OH, —NH 2 , alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, arylcarboxamido, hydrazino, alkylhydrazino, hydroxylamino, alkoxyamino, alkylthio, alkenyl, aryl, or alkyl.

5. The complex of claim 4 , wherein R 11 and R 15 are independently —H; R 12 and R 14 are the same and —H or methyl; and R 13 is —H, C1 to C12 alkoxy, —NH 2 , C1 to C12 alkylamino, C2 to C24 dialkylamino, hydrazino, C1 to C12 alkylhydrazino, hydroxylamino, C1 to C12 alkoxyamino, C1 to C12 alkylthio, or C1 to C12 alkyl.

6. The complex of claim 2 , wherein L 1 has the formula:

wherein R 11 , R 12 , R 13 , R 14 and R 15 are independently —H, methyl, C1-C2 alkoxy, C1-C2 alkylamino, C2-C4 dialkylamino, or a C1-C6 lower alkyl substituted with a reactive group.

7. The complex of claim 2 , wherein L 2 is —F, —Cl, or —Br.

8. The complex of claim 2 , wherein L 2 is —Cl.

9. The complex of claim 2 , wherein R′ 1 is a C1-C2 alkyl.

10. The complex of claim 2 , wherein R′ 1 is a C1 alkyl.

11. The complex of claim 2 , wherein each of R a and R c is —H.

12. The complex of claim 2 , wherein each of R a , R b , and R c is —H.

13. The complex of claim 2 , wherein each of R a , R b , R c , and R d is —H.

14. A complex having the formula:

wherein

M is cobalt, iron, osmium, ruthenium, or vanadium;

L 1 has the formula:

wherein R 11 , R 12 , R 13 , R 14 and R 15 are independently —H, —F, —Cl, —Br, —I, —NO 2 , —CN, —CO 2 H, —OH, —NH 2 , alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, arylcarboxamido, hydrazino, alkylhydrazino, hydroxylamino, alkoxyamino, alkylthio, alkenyl, aryl, or alkyl;

L 2 is chloride;

L and L′ are independently:

wherein R′ 1 is methyl; and R′ 3 , R′ 4 , R a , R b , R c , and R d are independently —H;

c is a negative, neutral, or positive charge represented by −1 to −5, 0, or +1 to +5, inclusive, respectively;

d is a number of X sufficient to balance the charge c; and

X is an anion.

15. The complex of claim 14 , wherein R 13 is C1-C2 alkylamino.

16. The complex of claim 14 , wherein R 11 , R 15 , R 12 , and R 14 are independently —H.

17. A complex having the formula:

wherein

M is osmium;

L 1 has the formula:

wherein R 11 , R 12 , R 14 and R 15 are —H;

R 13 is C1-C2 alkylamino;

L 2 is chloride;

L and L′ are independently:

wherein R′ 1 is methyl; and R′ 3 , R′ 4 , R a , R b , R c , and R d are independently —H;

c is +2;

d is 2; and

X is chloride.

18. The complex of claim 14 , wherein X is a halide.

19. The complex of claim 14 , wherein X is chloride.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2009
From: MAO, FEI; HELLER, ADAM
To: THERASENSE, INC.
Reel/Frame 022245/0410 →
CHANGE OF NAME Recorded Feb 11, 2009
From: THERASENSE, INC.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 022245/0464 →
Continuity (5)
Continuation 1136142700 · Feb 24, 2006
Continuation 1071483500 · Nov 14, 2003
Continuation 1014330000 · May 9, 2002
Provisional Application 6029053700 · May 11, 2001
Related Publication 20090143584A1 · Jun 4, 2009